This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Strength Seen in H Lundbeck AS (HLUYY): Can Its 11.2% Jump Turn into More Strength?
by Zacks Equity Research
H Lundbeck AS (HLUYY) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
H Lundbeck AS (HLUYY) Surges 12.5%: Is This an Indication of Further Gains?
by Zacks Equity Research
H Lundbeck AS (HLUYY) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Are These Medical Stocks Undervalued Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Are These Medical Stocks Undervalued Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
H. Lundbeck (HLUYY): Strong Industry, Solid Earnings Estimate Revisions
by Zacks Equity Research
H. Lundbeck (HLUYY) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
USANA Health (USNA) Soars to 52-Week High, Time to Cash Out?
by Zacks Equity Research
USANA Health (USNA) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Sanofi's MAA for Pompe Disease Candidate Gets EMA's Acceptance
by Zacks Equity Research
The European Medicines Agency accepts for review Sanofi's (SNY) marketing authorization application for avalglucosidase alfa as a long-term enzyme replacement therapy for treating Pompe disease.
Bayer's Drug Meets Primary Endpoint in Renal Outcomes Study
by Zacks Equity Research
Bayer's (BAYRY) investigational candidate, finerenone, meets primary endpoint in the phase III FIDELIO_DKD study in patients with CKD and T2D.
AstraZeneca's sNDA for Brilinta Gets FDA's Priority Review
by Zacks Equity Research
The FDA accepts AstraZeneca's (AZN) sNDA for Brilinta under a Priority Review to lower subsequent stroke in patients who experienced an acute ischemic stroke or transient ischemic attack.
H. Lundbeck (HLUYY): Strong Industry, Solid Earnings Estimate Revisions
by Zacks Equity Research
H. Lundbeck (HLUYY) has seen solid earnings estimate revision activity over the past two months, and belongs to a strong industry as well.
Is H. Lundbeck (HLUYY) a Profitable Pick for Value Investors?
by Zacks Equity Research
Let's see if H. Lundbeck (HLUYY) stock is a good choice for value-oriented investors right now from multiple angles.
Merck's Keytruda Clinches CHMP Nod for Difficult Lung Cancer
by Zacks Equity Research
Merck (MRK) secures a positive verdict from the Committee for Medicinal Products for Human Use to approve Keytruda's combo therapy for first-line treatment of a difficult lung cancer population.
Novo Nordisk (NVO) Q4 Earnings Miss Estimates, Revenues Beat
by Zacks Equity Research
Novo Nordisk (NVO) fourth-quarter 2018 results mainly benefit from strong performance by Ozempic.
Lilly (LLY) Hits 52-Week High, Can the Run Continue?
by Zacks Equity Research
Lilly (LLY) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Sanofi's (SNY) Influenza Vaccine Gets FDA Approval for Kids
by Zacks Equity Research
Sanofi's (SNY) influenza vaccine, Fluzone Quadrivalent (0.5mL dose), gains an FDA nod for treating children in six to 35-month age group.
AbbVie's Imbruvica Fails in Phase III Pancreatic Cancer Study
by Zacks Equity Research
AbbVie's (ABBV) Imbruvica falls short of meeting the primary endpoint of PFS or OS benefit in a phase III study that probed its combo usage in first-line metastatic pancreatic cancer.
Lilly Stops Lartruvo Promotion as Confirmatory Study Fails
by Zacks Equity Research
Eli Lilly's (LLY) Lartruvo combo is unable to demonstrate the clinical benefit for the primary endpoint of OS rate in a phase III study related to treating patients with metastatic soft tissue sarcoma.
Pfizer's Xtandi Gets FDA Nod for Expanded Patient Population
by Zacks Equity Research
FDA approves Pfizer's (PFE) sNDA to expand the label of Xtandi to include the non-metastatic prostate cancer patient population.
Amgen Resubmits BLA to FDA for Osteoporosis Candidate Evenity
by Zacks Equity Research
Amgen Inc. (AMGN) and its partner UCB announce the resubmission of the BLA to the FDA for Evenity to treat osteoporosis in postmenopausal women and in men at increased risk of fracture.
J&J (JNJ) to Pay $4.69 Billion to Some Women in Talc Lawsuit
by Zacks Equity Research
Johnson & Johnson (JNJ) has been ordered to pay $4.69 billion in damages to 22 families who alleged that the company's baby powder contained asbestos that caused them to develop ovarian cancer.
Will J&J's (JNJ) Pharma Segment Strength Drive Q2 Earnings?
by Zacks Equity Research
The positive trend seen in J&J's (JNJ) pharma segment sales in the past three quarters is likely to continue in Q2
3 Buy-Rated Large Cap Pharma Stocks to Boost Health in July
by Madhu Goel
We take a look at the three large cap pharma stocks that might be best bargains for the month of July.
Lilly's (LLY) Taltz Positive in Ankylosing Spondylitis Study
by Zacks Equity Research
Lilly (LLY) posts positive top-line results from a second phase III study on Taltz for the treatment of Ankylosing Spondylitis (AS).
Pfizer's Leukemia Candidate Gets Priority Review From FDA
by Zacks Equity Research
The FDA grants a priority review to Pfizer's (PFE) NDA for leukemia candidate glasdegib for the first-line treatment of acute myeloid leukemia (AML) in combination with chemotherapy.
AbbVie's (ABBV) Imbruvica sNDA Gets Priority Review From FDA
by Zacks Equity Research
The FDA grants a priority review to AbbVie's (ABBV) lymphoma drug Imbruvica sNDA, for the treatment of Waldenstr??m's macroglobulinemia (WM).